PTC THERAPEUTICS, INC. — Director's Dealing 2025

Oct 9, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PTC THERAPEUTICS, INC. (PTCT)
CIK: 0001070081
Period of Report: 2025-10-07

Reporting Person: Boulding Mark Elliott (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-10-07	Common Stock	M	3375	$38.10	Acquired	107276	Direct
2025-10-07	Common Stock	S	1757	$62.89	Disposed	105519	Direct
2025-10-07	Common Stock	S	1306	$63.80	Disposed	104213	Direct
2025-10-07	Common Stock	S	312	$64.97	Disposed	103901	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-10-07	Stock Option (Right to Buy)	$38.10	M	3375	Disposed	2032-01-06	Common Stock (3375)	Direct

Footnotes

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $62.36 to $63.28 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F3: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $63.36 to $64.25 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F4: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.56 to $65.01 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F5: This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.